This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Beyer J, Kingreen D, Krause M, Schleicher J, Schwaner I, Schwella N et al. Long term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Cancer 1997; 79: 161–168.
Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R . High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357: 340–348.
Feldmann DR, Powles T . Salvage high-dose chemotherapy for germ cell tumors. Urol Oncol 2015; 33: 355–362.
Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 2011; 29: 2178–2184.
Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000; 18: 1173–1180.
Vaena DA, Abonour R, Einhorn LH . Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol 2003; 21: 4100–4104.
Nichols CR, Andersen J, Lazarus HM, Fisher H, Greer J, Stadtmauer EA et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol 1992; 10: 558–563.
Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 1996; 14: 2638–2645.
Beyer J, Stenning S, Gerl A, Fossa S, Siegert W . High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann Oncol 2002; 13: 599–605.
Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IG, Berdel WE et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol 2007; 25: 2778–2784.
Lorch A, Kleinhans A, Kramar A, Kollmannsberger CK, Hartmann JT, Bokemeyer C et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol 2012; 30: 800–805.
International Prognostic Factors Study Group Lorch A Beyer J Bascoul-Mollevi C Kramar A Einhorn LH et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 2010; 28: 4906–4911.
Pico JL, Rosti G, Kramar A, Wandt H, Koza V, Salvioni R et al. A randomized trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors. Ann Oncol 2005; 16: 1152–1159.
Lotz JP, Bui B, Gomez F, Théodore C, Caty A, Fizazi K et al. Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial. Ann Oncol 2005; 16: 411–418.
Lazarus HM, Stiff PJ, Carreras J, Logan BR, Akard L, Bolwell BJ et al. Utility of single versus tandem autotransplants for advanced testes/germ cell cancer: a center for international blood and marrow transplant research (CIBMTR) analysis. Biol Blood Marrow Transplant 2007; 13: 778–789.
Acknowledgements
We thank Helen Baldomero, Irene Briner and Doris Jaeggi-Meinken for their generous help with the data collection, and Martin Bigler (statistician, SAKK) for assistance with the statistical analysis. This work was supported by grants from the Bernische Stiftung für Klinische Krebsforschung (to TP), from the Krebsliga Bern (to TP) and from the EMPIRIS Foundation/Ursula-Hecht-Fonds (to TP).
Author contributions
FG: performed the research, analyzed the data and wrote the paper; MS, MZ and JS: contributed vital material, analyzed the data and reviewed the paper; SP, AM, FS, UH, DB and MB: contributed vital material and reviewed the paper; TP: designed the research, analyzed the data and wrote the paper.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on Bone Marrow Transplantation website
Supplementary information
Rights and permissions
About this article
Cite this article
Gössi, F., Spahn, M., Zweifel, M. et al. Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse. Bone Marrow Transplant 52, 334–336 (2017). https://doi.org/10.1038/bmt.2016.285
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.285